Moreover, anti-CEA CAR-T cell therapy demonstrated a significant beneficial effect in a patient with liver metastases secondary to stage IV pancreatic adenocarcinoma, and who received locally infused CEA CAR-T cells at the site of a solid tumor by Pressure-enabled Drug Delivery (PEDD) [69]. This evidence concerns the gene CEACAM5 and pancreatic adenocarcinoma.